RCT | JAK inhibitor Upadacitinib shows superiority over placebo for moderate-to-severe Crohn’s disease
1 Jun, 2023 | 12:08h | UTCUpadacitinib Induction and Maintenance Therapy for Crohn’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)